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In spite of being derived from self-tissue, tumours have been
shown to express antigenic determinants, defined as tumour asso-
ciated antigens (TAAs) which distinguish them from normal cells.
TAAs are often expressed at high levels in tumours relative to
normal tissue. Some TAAs are differentiation antigens that reflect
the cell of origin, while others are molecules usually confined to
normal undifferentiated cells during development and are termed
onco-fetal antigens (Boon and Old, 1997). MUC1 falls into a third
category of TAAs which are expressed at high levels on solid
epithelial tumours and present an altered pattern of glycosylation
(Burchell et al, 1987).
The MUC1 gene encodes the membrane bound, polymorphic
epithelial mucin which contains an extended domain comprised of
a variable number of a conserved 20 amino acid repeats (Gendler
et al, 1987, 1988). Under normal circumstances, MUC1 is expres-
sed on the luminal surface of most glandular epithelial cells but
MUC1 has also been found on activated lymphocytes and has been
proposed to be involved in the induction of T cell anergy (Agrawal
et al, 1998b). The monoclonal antibody (mAb) HMFG1 binds to
the linear core protein sequence, PDTR, contained within the
immunodominant domain of the tandem repeats of MUC1
(Burchell and Taylor-Papadimitriou, 1993). HMFG1 has been
used both to localize ovarian cancers by radioimmunoscintigraphy
(Boyle et al, 1992) and for radiotherapy (Kosmas et al, 1998).
The unique complementarity determining regions (CDRs) within
antibody variable regions can trigger a cascade of inter-reactive or
anti-idiotypic antibodies. The idiotypic network comprise an anti-
body to antigen (Ab1) which in turn functions as an immunogen to
elicit a second antibody (Ab2) specific to Ab1. In addition, a third
wave of antibodies (Ab3) specific for Ab2 may be induced and
these AB3 antibodies may cross-react with the original antigen
(Jerne, 1974). Anti-idiotypic antibodies are thought to play a role in
antibody regulation and provide extended antigenic exposure after
clearance of the original foreign antigen (Bona, 1998). It has been
hypothesized that prolonged anti-tumour immunity seen in some
cancer patients and in animal models may reflect the development
of idiotypic antibody networks (Mellstedt, 1995).
Although monoclonal antibody-based tumour immunotherapy
has been studied for many years, animal models which allow
human TAAs to be targeted in studies on immunotherapies
involving anti-idiotype vaccination in tolerant, immunocompetent
hosts have only recently been developed (Peat et al, 1992; Eades-
Perner et al, 1994). The availability of mice transgenic for human
MUC1, which are fully immunologically responsive and yet
tolerant to human MUC1 (Peat et al, 1992; Rowse et al, 1998) now
allows a detailed analysis of immune mechanisms which could be
relevant to immunotherapy. Presented here is a pre-clinical study
using murine and humanized HMFG1 as an idiotypic vaccine. The
effects of route of antibody injection and various adjuvant formula-
tions on idiotypic network formation and subsequent tumour clear-
ance within a fully immunotolerant transgenic model are described.
MATERIAL AND METHODS
Animals
Human MUC1 transgenic mice (SacII) (CBA, H-2k) were back-
crossed with Balb/c (H-2d) mice (non-Transgenic, non-Tg) to form
a colony of SacII × Balb/c F1 (H-2k, H-2d) mice (MUC1.tg) (Peat 
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1 Authors contributed equally to the work.et al, 1992; Graham et al, 1995). All MUC1.Tg and non-Tg mice
used in experiments were 8–10-week-old females. Mice were
housed and maintained in microisolator cages under pathogen-free
conditions.
Monoclonal antibodies
Antibodies used in this study were murine (m) (IgG1) and human-
ized (h) (IgG1) monoclonal anti-human MUC1 mAb, HMFG1
(Taylor-Papadimitriou et al, 1981; Burchell et al, 1983, 1987) and
a murine (IgG1) and humanized (IgG1) monoclonal anti-
carcinoembryonic antigen (CEA) antibody (clone PR1A3), as an
isotype-matched control (i.c.) (Stewart et al, 1999). The hHMFG1
was obtained by transferring the complementarity determining
regions (CDR) of the mouse antibody HMFG1 onto human frame-
work regions (Verhoeyen et al, 1993). Antibodies were purified
from cell culture supernatant by protein A affinity chromato-
graphy, gel filtration and ion exchange chromatography. Antibody
used in immunization experiments was sterile and endotoxin free.
Human MUC1+ murine tumour cell line
The E4 cells used in these studies were derived from the murine
mammary epithelial cell line, 4104.4 (Balb/c, H-2d), which was
transfected with the gene for human MUC1 (Lalani et al, 1991).
Mice were injected subcutaneously (s.c.) with 2 × 105 cells in
100 µ l of PBS to establish solid tumours. Tumours were measured
every 3–4 days with vernier calipers by animal technicians who
were unaware of the treatment and control groups. Tumour
volumes were calculated as (a × b2)/2, where a represents the
largest and b the smallest diameter. Human MUC1 expression
was confirmed by flow cytometry on E4 cells before injection
(FACScan, Becton Dickinson) using hHMFG1 followed by FITC-
conjugated sheep anti-human IgG (Sigma). Expression of MUC1
in solid tumours was confirmed after 80 days of tumour growth
by standard peroxidase anti-peroxidase immunohistochemical
labelling of frozen tumour sections with hHMFG1.
Immunizations and adjuvants
Animals received antibodies diluted in PBS with or without adju-
vant in a final volume of 200 µ l. Alum (Alhydrogel 2%, Superfos,
Denmark) was mixed with antibody in a 1:1 ratio, RIBI Adjuvant
System (RAS) contained synthetic trehalose dicorynomycolate
(TDM) and monophoshoryl lipid A (MPL) in oil and Tween 80
and was prepared in accordance with the supplier’s guidelines
(R-700, RIBI Immunochem Research, Hamilton, USA). Provax
(IDEC Pharmaceutical, San Diego, USA), which was a gift from
Dr WJW Morrow, Queen Mary and Westfield College, London,
had a composition of squalane (15% wt/vol), Tween 80 (0.6%)
and pluronic acid L121 (3.75%) (Raychaudhuri et al, 1992).
Antibody/adjuvant formulations were injected intraperitoneally
(i.p.) or subcutaneously (s.c.) at two week intervals on four occa-
sions over six weeks, and blood samples were obtained an hour
before each injection. Four weeks after the final injection the
animals were challenged with human MUC1+ E4 cells.
Detection of AB2 and AB3 antibodies by ELISA
Antibodies specific for HMFG1 were detected on 96-well
microtitre plates coated with F(ab) fragments from HMFG1. F(ab)
fragments were generated by digestion of HMFG1 (4 mg/ml in
0.1 M sodium acetate, pH 6.5, 3 mM EDTA, 50 mM DTT) with
papain (0.2 mg/ml) for 4 hours at 37° C, and purified by Superose
and MonoQ chromatography. A glutathione-S-transferase-MUC1
fusion protein (GST-MUC1) was employed for the detection of
HMFG1 and Ab3 (Apostolopoulos et al, 1993). DNA coding for
the seven tandem repeats of the 20 amino acid peptide epitope was
inserted into the GST fusion vector pGEX-4T-1 (Pharmacia) and
expressed in E. coli TG1 grown in L broth supplemented with 0.5
mM IPTG (Sigma). Following lysis with lysozyme in 1% Triton
X-100 buffer, the fusion protein was affinity purified from super-
natant using a glutathione-Sepharose 4B column (Pharmacia) and
stored at 4° C in the presence of 2 mM glutathione until use.
Microtitre plates were coated overnight at 4° C with F(ab) frag-
ments or GST-MUC1 (20 µ g/ml in PBS) and blocked for 1 hour
with 200 µ l of 2% BSA in PBS. All plate washes and dilutions were
performed with 0.02% Tween 20 in PBS. Serial dilutions of posi-
tive control antibodies, pre-treatment and post-treatment sera were
prepared and 50 µ l was added to each well. Antibody binding was
detected with alkaline phosphatase conjugated anti-mouse pan-IgG
(Sigma, UK) and p-nitrophenyl phosphate substrate (Sigma, UK).
The subclasses of the Ab2 and Ab3 antibodies were determined
using the above method with alkaline phosphatase conjugated anti-
mouse IgG1, IgG2a IgG2b and IgG3 (Pharmingen, Cambridge
Bioscience, UK) antibodies. Anti-MUC1 subclass control antibodies
(Karsten et al, 1998) were kindly supplied by Dr Franz-Georg
Hanisch (Institute of Biochemistry, Germany).
Statistical methods
Group means were compared using Students’ two-tailed, unpaired
t-test for normal data sets and the Mann-Whitney U-test for non-
parametric data. The degree of linear relationship between two data
sets was determined by calculation of a Pearson correlation coeffi-
cient which has an absolute value between 0 and 1 (+ or –) with 1
indicating a perfect linear relationship. The Fisher’s r to z transfor-
mation was performed to obtain a probability level (P value) for the
null hypothesis that the correlation is equal to zero. Probability
values less than 0.01 were interpreted as significant. All statistics
were performed using the SPSS statistical package.
RESULTS
Transgenic animals are tolerant to MUC1
Pre-existing antibody reactivity to MUC1 was not detected in
either normal non-Tg mice (n = 10) or MUC1.Tg mice (n = 10).
Following challenge with hMUC1-transfected E4 tumour cells, all
non-Tg mice produced variable but significant levels of antibodies
reactive with GST-MUC1, whereas no evidence of anti-MUC1
antibody production was observed in transgenic animals (Fig. 1A).
Isotype analysis of the anti-MUC1 immunoglobulin response in
the non-Tg mice demonstrated the presence of IgG1, IgG2a,
IgG2b and IgG3 (Fig. 1B).
Generation of anti-F(ab) and anti-MUC1 antibodies in
MUC1.tg mice
Antibodies (Ab2) specific for the F(ab) fragment of mHMFG1 or
hHMFG1 and GST-MUC1 (Ab3) were induced in MUC1.Tg mice
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without adjuvant. Highest levels of anti-MUC1 Ab3 antibodies
were detected after immunization with mHMFG1 with RAS adju-
vant which contrasted with the low to negligible Ab3 levels
produced following injection with isotype and diluent controls
(Fig. 2). Sera from immunized mice did not bind to a F(ab) frag-
ment of an isotype-matched control antibody or a control antigen
(CEA) (data not shown). This confirms that the responses detected
were true Ab2 and Ab3 responses specific for HMFG1 and
MUC1 respectively. The magnitude of anti-idiotypic and anti-
anti-idiotypic responses was proportional to the amount of HMFG1
injected. Mice which received 100 µ g of HMFG1 produced higher
levels of Ab2 and Ab3 antibodies than those which received 10 µ g
or 40 µ g of HMFG1 (data not shown). Serum Ab2 levels always
exceeded Ab3 levels and a positive correlation was observed
between Ab2 and Ab3 (Pearson correlation coefficient: non-Tg r2 =
0.502; MUC1.Tg r2 = 0.806; P < 0.001) (Fig. 2B).
Factors effecting the generation of Ab2 and Ab3
antibodies
The levels of Ab2 and Ab3 antibodies obtained were influenced 
by the number of injections, the adjuvant used and the route of
administration. HMFG1 was administered on four occasions at
least two weeks apart, either i.p. or s.c., in combination with three
different adjuvants: Alum, Provax and RAS (Fig. 3A and B).
Highest levels of Ab2 and Ab3 antibody were obtained following
three injections of mHMFG1 with RAS adjuvant (Fig. 3C). Any
contribution of residual circulating HMFG1 to the Ab3 levels was
thought to be minimal since the half-life of the antibody was 7
days (data not shown). However, residual antibody could account
for the slightly lower values measured four weeks after the last
injection in comparison to values seen two weeks after the third
injection.
A comparison of adjuvant and route of immunization demon-
strated that i.p gave better Ab3 responses than s.c. and these
responses were heightened by the addition of an adjuvant (Fig. 3).
The potentiation of Ab3 responses with adjuvant on s.c inoculation
was much less evident. The optimal conditions for Ab3 induction
were i.p immunization with RAS in preference to alum or Provax.
This was achieved with antibody concentrations of 100 µ g per
1204 RW Wilkinson et al
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Figure 1 ELISA analysis of anti-MUC1 antibody produced by non-Tg and
MUC1-Tg mice after inoculation with MUC1 transfected tumour cells and pre-
inoculation normal serum controls. (A) Total IgG levels, and (B) isotype
analysis. Groups contained 10 mice and standard errors for mean
absorbance values are shown
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Figure 2 MUC1.Tg mice were injected i.p. on three occasions, two weeks
apart, with mHMFG1 + RAS. (A) Titration of anti-MUC1 antibody, control sera
include pre-immune sera groups immunized with either an isotype-matched
control antibody PR1A3 (anti-CEA antibody) or PBS. Groups contained 8
mice and standard errors for mean absorbance values are shown.
(B) Positive correlation between Ab2 and Ab3 levels in immunized MUC1.Tg
mice. MUC1.Tg mice (10/group) were inoculated i.p. with mHMFG1 with and
without RAS adjuvant, or with murine isotype control antibody with and
without RAS, or PBS with and without RAS adjuvant, on four occasions two
weeks apart. Sera samples were assayed at dilutions of 1/50dose, and lesser responses occurred with lower doses of antibody
(data not shown). Ab2 levels were much less influenced by route
and equivalent values were found for both s.c and i.p. immuniza-
tion. Significantly, a comparison of murine and humanized
HMFG1 given with RAS demonstrated that the murine antibody in
a mouse was a more effective inducer of an Ab3 response than the
humanized antibody (Fig. 3).
Effect of adjuvant on anti-MUC1 antibody (Ab3) isotype
The isotype profile was determined for the Ab2 and Ab3 anti-
bodies produced in MUC1.Tg mice after i.p. immunization on four
occasions. The isotype of the Ab2 induced was IgG1 in the
majority of cases (Fig. 4). However, adjuvant influenced the
isotype profile in that i.p. injection of mHMFG1 with RAS
produced IgG2a and IgG2b Ab2 antibodies. The Ab3 isotypes
from mice which received mHMFG1 plus adjuvant were almost
Anti-idiotype responses to MUC1 in transgenic mice 1205
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Figure 3 The effect of adjuvant and number of inoculations on the
production of Ab2 and Ab3 antibodies by MUC1.Tg mice. Mice (10/group)
received four injections either i.p. (A), or s.c. (B), of 100 µ g murine (m) or
human (h) HMFG1 with or without adjuvant (RAS, Provax, Alum). (C) Ab2
and Ab3 levels increase with the number of HMFG1 injections. MUC1.Tg
mice (10/group) were injected i.p. with 100 µ g of mHMFG1 + RAS.
Inoculations were two weeks apart and sera samples were taken two weeks
after injection, except for the final samples which were taken four weeks after
the final injection. Sera samples were assayed at 1/50 dilution and mean
absorbance values ± standard errors are shown.
Figure 4 The isotype of the Ab2 (A) and Ab3 (B) antibodies generated in
MUC1.Tg (10/group) mice after four i.p. immunizations with either murine or
human HMFG1 with or without adjuvant (RAS; Provax; Alum). Mean
absorbance values ± standard errors are shownexclusively IgG1 with only very low levels of IgG2a and G2b
detected which did not vary significantly for the different adju-
vants used. Mice receiving hHMFG1 plus RAS only produced
IgG1 Ab2 and Ab3 antibodies. No IgG3 Ab2 or Ab3 antibodies
were detected in any of the samples.
Tumour development following immunization schedule
Tumour growth kinetics and survival were determined for immu-
nized mice by giving a single s.c. inoculation of 2 × 105 E4 tumour
cells four weeks after the final immunization. All mice developed
solid, highly vascularized tumours within 28 days. Tumour size at
35 days was compared between mice which had received i.p.
injections of mHMFG1 with or without RAS, murine isotype
control antibody with or without RAS and PBS with or without
RAS. Although the mean tumour size in mice immunized
with mHMFG1 was smaller than those from mice immunized with
diluent (PBS) and isotype control antibody, the difference was
not significant (mHMFG1/PBS, P = 0.198; mHMFG1/i.c., P =
0.1849). In contrast, tumours grown in mice which received
mHMFG1 + RAS were significantly smaller than all control
groups (mHMFG1 + RAS/PBS, P = 0.015, mHMFG1 + RAS/PES
+ RAS, P = 0.003, mHMFG1 + RAS/i.c., P = 0.017, mHMFG1 +
RAS/i.c. + RAS, P = 0.001).
Ab3 levels in the mHMFG1 + RAS treatment group was signi-
ficantly higher than the control groups (mHMFG1 + RAS/PBS, P
= 0.001, mHMFG1 + RAS/PBS + RAS, P = 0.002, mHMFG1 +
RAS/i.c., P = 0.002, mHMFG1 + RAS/i.c. + RAS, P = 0.006).
Ab3 levels generated in the mHMFG1 treatment group were
significantly higher when compared with the diluent control
(mHMFG1/PBS, P = 0.03) but no statistically significant differ-
ences were found between mHMFG1 and the other control groups
(mHMFG1/PBS + RAS, P = 0.275, mHMFG1/i.c., P = 0.301,
mHMFG1/i.c. + RAS, P = 0.840) (Table 1). In spite of the fact that
smallest tumours and highest AB3 levels occurred in the HMFG1
+ RAS group, when individual samples from this treatment group
were examined, a negative correlation did not exist between
tumour size and AB3 levels. Furthermore, when tumour size at
day 35 and AB3 levels from individual mice from all treatment
groups (mHMFG1 alone and with adjuvants) were compared, no
inverse correlation was found (Pearson correlation coefficient r2 =
0.084; P = 0.685) (Fig. 5). When the effect of adjuvant within the
controls was analysed no statistically significant difference was
observed in tumour growth (PBS/PBS + RAS, P = 0.130, i.c./i.c. +
RAS,  P = 0.053). Comparison of Ab3 levels between control
groups with and without RAS revealed that the groups given the
adjuvant had significantly higher Ab3 levels than non-RAS
growth (PBS/PBS + RAS, P = 0.0003, i.c./i.c. + RAS, P = 0.0156).
DISCUSSION
A number of groups have explored the possibility of utilizing anti-
idiotypic vaccines for the treatment of cancer either as antibodies
specific for TAA (Ab1) or ‘internal image’ antibodies which
mimic TAAs (Ab2) (Mellstedt, 1995; Bona, 1998). Some success
has been attributed to anti-Id therapy, for instance, patients with
Dukes’ C colorectal cancer receiving adjuvant treatment with the
murine mAb 17-1A (anti-Ep-CAM) showed a 30% improvement
in overall survival and an equivalent reduction in distant
metastatic recurrence (Riethmuller et al, 1994). This study and
others have established the safety of an anti-id approach, but the
immune and anti-tumour responses stimulated by these therapies
have yet to be clearly defined. This in part is because studying
anti-idiotype vaccination against human TAAs has been difficult
in animal models since a fully competent immune system is
needed.
MUC1 transgenic mice appear to be fully tolerant to human
MUC1 in that they do not develop a humoral response to the
antigen despite it being aberrantly glycosylated within the tumour
microenvironment (Graham et al, 1996). This result was inter-
esting since some humans have been reported to produce anti-
bodies to under-glycosylated MUC1 (von Mensdorff-Pouilly et al,
1996). To more accurately mimic tumour growth in humans, an
adenocarcinoma line was chosen (Miller et al, 1983; Lalani et al,
1991). This line not only grows slowly in vivo (tumour related
death does not take place until 40 to 80 days after inoculation of
2 × 105 cells) but expresses low levels of class I antigen at its
surface. This makes the tumour line transfected with MUC1 ana-
logous to a poorly differentiated, invasive breast carcinoma
(Garrido et al, 1993). A key factor in the use of this tumour is that
even after 80 days growth in vivo tumour cells maintain surface
expression of human MUC1 and thus remain good targets for
immunotherapy.
Vaccination with HMFG1 can break tolerance to MUC1 in the
MUC1.Tg mice with the appearance of Ab2 and Ab3 antibodies.
These responses were influenced by the number of injections, the
route of injection, and by the adjuvant used. Using this model,
we found that induction of significant anti-MUC1 Ab3 antibody
1206 RW Wilkinson et al
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Table 1 AB3 levels and tumour size in MUC1.Tg mice following mHMFG1
treatment
Treatment AB3 (OD405nm)a Tumour size (cm3)b
mHMFG1 0.156 ± 0.057 0.132 ± 0.041
mHMFG1 + RAS 0.695 ± 0.160 0.100 ± 0.029
ic.c mIgG1 0.088 ± 0.027 0.199 ± 0.031
ic. mIgG1 + RAS 0.169 ± 0.022 0.311 ± 0.035
PBS 0.021 ± 0.005 0.211 ± 0.032
PBS + RAS 0.088 ± 0.027 0.278 ± 0.033
a Mean (n = 10) ± s.e. AB3 levels in 1:50 diluted sera obtained 4 weeks after
the final antibody injection and before challenge with E4 cells. b Mean
(n = 10) ± s.e. tumour volume was calculated 35 days after challenge with
2 × 105 E4 cells. c i.c.: isotype-matched control.
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Figure 5 Comparison of tumour size and AB3 levels. MUC1.Tg mice
received four i.p. injections of murine HMFG1 with or without adjuvant (RAS;
Provax; Alum) followed by one s.c. injection of 2 × 105 tumour cells. Levels of
serum anti-MUC1 Ab3 antibodies were assessed immediately before
administration of E4 cells. Tumour volumes 35 days following cell injection
are compared with Ab3 antibody levels for individual miceAnti-idiotype responses to MUC1 in transgenic mice 1207
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responses required at least three 100 µ g doses of antibody, that i.p.
immunization was better than s.c., and that a strong adjuvant gave
a heightened response. Interestingly, higher levels of AB3 were
obtained using murine as compared to humanized antibody. This
suggests that homologous rather than heterologous antibody
would be the better antibody to use in an idiotypic vaccination
programme. The superior performance of murine antibody in
mouse may be influenced by the strong MAHA (mouse anti-
human antibody) response given when the heterologous antibody
is used (data not shown), which may compete with or inhibit the
idiotypic cascade.
TAAs targeted for anti-idiotype immunotherapy in clinical trials
include melanoma-associated chondroitin sulphate proteoglycan
(MPG) (Pride et al, 1998), carcinoembryonic antigen (CEA) (Foon
et al, 1997) and the disialogangliosides GD2 (Chapman et al,
1994) and GD3 (Foon et al, 1998). The adjuvants used in these
studies have been shown to be effective in increasing humoral
responses. For example, the adjuvant QS-21 administered with an
anti-GD3 Ab2 antibody induced Ab3 antibodies in all patients
studied. Within this group of 12 melanoma patients, one made a
complete clinical response with soft tissue resolution, while six
had stable disease ranging from 9 to 23 months (Foon et al, 1998).
The most effective adjuvant in our study, RAS, is a mycobac-
terium derivative in an oil and water mix which has previously
been used in human cancer vaccine trials and has been reported to
augment protective antibody responses (Daly and Long, 1996;
Miles et al, 1996). It has previously been shown that type 1
responses are characterized by the production of IgG2a antibodies,
whereas IgG1 is present in both type 1 and type 2 immune
responses (Rodolfo et al, 1998). Immunization with HMFG1 in
transgenic mice resulted in Ab2 and Ab3 antibodies which were
predominantly IgG1 and the presence of RAS induced small quan-
tities of IgG2a and IgG2b Ab2 antibodies.
When the antibody responses for individual animals were
compared, it was clear that there was a direct correlation between
the level of Ab2 and Ab3 in that a strong Ab2 response was asso-
ciated with a strong Ab3 response. Highest Ab3 levels and slowest
tumour growth occurred in MUC1.tg mice after vaccination with
murine HMFG1 plus RAS. However, this inhibition could not be
attributed solely to the induction of anti-MUC1 Ab3 antibodies in
an idiotypic cascade since no significant correlation between Ab3
levels and tumour retardation was observed when the mice were
examined on an individual level. In addition to humoral responses,
it has been suggested that anti-Id therapy can activate cellular
immunity to TAAs (Pride et al, 1998; Ruiz et al, 1998). This may
explain why some mice within the murine HMFG1 plus RAS
group, despite having low Ab3 antibody levels, were better
protected against tumour challenge than others with high Ab3
levels.
Regardless of the type of treatment administered in this
study, an induced anti-MUC1 response resulting from idiotypic
vaccination did not confer complete protection when mice were
challenged with the syngeneic hMUC1+ E4 tumour line. The
contribution of anti-MUC1 humoral response in MUC1 tumour
biology is controversial. Mice with high Ab3 levels did not appear
to have a significant survival advantage, and passive transfer of
polyclonal sera from a non.Tg mouse primed with hMUC1+ B16
cells into MUC1.Tg mice did not confer protection against trans-
planted hMUC1+ tumours (Tempero et al, 1999). In humans, circu-
lating anti-MUC1 IgG antibodies have been associated with a
good prognosis in early stage breast cancer patients, but not with
advanced stage disease at first diagnosis (von Mensdorff-Pouilly
et al, 2000). The disparity between these two results may reflect
tumour load.
As the immune response to solid tumours is dissected, it has
become evident that tumours employ a myriad of escape
mechanisms which thwart an active immune response. Under-
glycosylation of MUC1 and its elevated expression in epithelial
malignancies make tumour-associated MUC1 a reasonable target
for cancer immunotherapy (Agrawal et al, 1998a), but it is evident
that production of an anti-idiotype response alone is insufficient to
mount a therapeutic anti-tumour effect. This observation is further
complicated by the recent reports that MUC1 is expressed and
secreted by activated T cells and may have immunoregulatory
properties (Agrawal et al, 1998b). MUC1 has also been shown to
induce T cell anergy and interfere with NK-mediated lysis (Zhang
et al, 1997) which could have a significant impact on tumour
therapy and may even help to protect the MUC1+ tumour from
cell-mediated attack.
The most effective immunotherapies are likely to employ more
than one aspect of the immune system. Activated CD4+ T cells
(Hung et al, 1998) and APC/tumour cell fusions have recently
been shown to be important in primary stimulation of an anti-
tumour response (Gong et al, 1998). Furthermore, CTLs
effectively protected animals from tumour challenge, but both
antibodies and CTLs were required to eliminate established
tumours (Vasovic et al, 1997). It is possible that anti-MUC1 anti-
bodies produced by an idiotyic cascade could provide protection
against tumour growth in minimal residual disease, but this may
rely upon synergy with effector cells.
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